NASDAQ:INKT
MiNK Therapeutics, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
minktherapeutics.comipo date
Oct 15, 2021
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus